Daily News header

Controversial Drug Now Marketed for Depression

By

First approved for schizophrenia in 1997, AstraZeneca's antipsychotic Seroquel has subsequently been approved for bipolar disorder, as an add-drug for depression and for some groups of kids. Nor is the public necessarily aware of the "indication creep." Seroquel approval for use in children in late 2009 was noted as a mere "label change" on the FDA web site.

Even though Seroquel is the fifth best-selling medication in the US according to drugs.com, exceeded only by Lipitor, Nexium, Plavix and Advair diskus, its safety, effectiveness, clinical trial and promotion records are highly checkered.

An original backer, psychiatrist Richard Borison, was sentenced to a 15-year prison sentence in 1998 for a pay-to-play Seroquel research scheme.

FDA2

Its US medical director Wayne MacFadden had sexual affairs with two different women involved with Seroquel research, say published reports.

Chicago psychiatrist Michael Reinstein received $500,000 from AstraZenenca and wrote 41,000 prescriptions for Seroquel reports the Chicago Tribune and ProPublica.

Psychiatrist Charles Nemeroff who left Emory University in disgrace after a Congressional investigation for unreported pharma income, promoted Seroquel in continuing medical education courses according to the web site of psychiatrist Daniel Carlat.

Florida child psychiatrist Jorge Armenteros was chairman of the FDA committee responsible for recommending Seroquel approvals while a paid AstraZeneca speaker himself, said the Philadelphia Inquirer in 2009.

Psychiatrist Charles Schulz' high profile pro-Seroquel presentations are suspected of being colored by his AstraZeneca income says the Minneapolis Star Tribune.

And unexplained Iraq and Afghanistan troop deaths are linked to Seroquel reported the Associated Press in August.

Now, as AstraZeneca rolls out its "Still Trying to Get Ahead of Your Depression" campaign, there are new questions about Seroquel's safety and effectiveness.

According to an FDA warning letter, an AstraZeneca sales representative during an unsolicited sales call on January 3, 2008 sold Seroquel as a treatment for major depressive disorder to a physician before it was approved for MDD, an infraction which is illegal.

Once Seroquel was approved for depression (as an add-on treatment to an antidepressant for patients with major depressive disorder who not have an adequate response to antidepressant therapy), its leave-behind sheets drew another FDA warning letter.

AstraZeneca implied patients would achieve "remission" from depression with Seroquel XR (extended release) as opposed to with an antidepressant alone, says FDA - a claim not backed up by clinical experience.

Seroquel's effect on depression has only been demonstrated in two, six-week trials FDA further said and six weeks is "not a long enough time period to adequately assess remission." (It was approved...why?)

Also the case study of "Catherine F." depicted in leave-behind sheets is inaccurate says FDA because it suggests Seroquel alleviates "symptoms of sadness and loss of interest when this has not been demonstrated by substantial evidence or substantial clinical experience." (It was approved...why?)

Even AstraZeneca's own briefing to the FDA committee in 2009 admits a "failed study" in which both Seroquel and Lexapro "failed to differentiate from placebo" which is Clinical Trial for "didn't work."

Nor did AstraZeneca adequately disclose Seroquel risks says FDA which include increased mortality in elderly patients with dementia-related psychosis, suicidality, neuroleptic malignant syndrome, hyperglycemia and diabetes mellitus, hyperlipidemia, weight gain and other serious side effects.

In fact, in addition to risks like cataracts, seizures and increases in blood pressure in children and adolescents, already on the Seroquel label, FDA asked AstraZeneca to add the "risk of EPS and withdrawal syndrome in neonates" a few months ago: movement disorders which can affect mothers' babies if the mothers are taking Seroquel and stop.

Even without its depression indication, Seroquel is big business for AstraZeneca, earning $4.9 billion in sales in 2009. It is the drug that North Carolina's Medicaid spends the most on: $29.4 million per year, reports the Charlotte News and Observer.

But adding the new indication to a drug whose dangers and effectiveness have already been so misrepresented and occluded is just, well, depressing.

Martha Rosenberg is a columnist and cartoonist, who writes about public health

  Please leave a comment here     If it does not display within 10 seconds, please refresh the page

Related Health News News

The deadline for the realization of the eight Millennium Development Goals (MDGs) by countries of the world is drawing to a close in 2015. The progress on MDGs might have been with mixed results, but lot of lessons need to be learnt while we frame n
In the year 2000, countries of the world had agreed to meet the 8 Millennium Development Goals (MDGs) by 2015. Numerous consultative processes have been taking place around the world on what should be the development goals post-2015.
Martha Rosenberg investigates a proposal that people watch the animals they eat being killed. Some say it encourages insensitivity and lack of empathy for suffering.
The first estimates of the global burden of TB in children given by the WHO in 2012, suggested that there might be 530,000 children suffering from it. Subsequently there has been an uptake in the research in this field.
We know that nearly one third of the 35 million people living with HIV (PLHIV) have tuberculosis (TB), and 13% of 8.6 million new TB cases every year are HIV positive. Also 1 in 5 HIV associated deaths are due to TB.
Ebola is big news in the U.S. just now because two infected missionary aid workers were brought to Atlanta for treatment and to study the disease. But it is not NEW to Africa. Ebola is very deadly; however, it is just another virus infection.

 

NewsBlaze Writers Of The Month



Popular Stories This Month

newsletter logo

NewsBlaze
Copyright © 2004-2014 NewsBlaze Pty. Ltd.
Use of this website is subject to our Terms of Service and Privacy Policy  | DMCA Notice               Press Room   |    Visit NewsBlaze Mobile Site